

# Pilot study of efficacy of anakinra in acute gouty arthritis

<b>Submission date</b> 21/11/2006	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 04/01/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 29/11/2007	<b>Condition category</b> Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Alexander So

**Contact details**  
Rheumatology Service  
Centre Hospitalier Universitaire Vaudois (CHUV)  
Av Pierre Decker  
Lausanne  
Switzerland  
1011

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
2006-1

## Study information

## **Scientific Title**

### **Study objectives**

Treatment with anakinra will decrease the signs and symptoms of acute gout.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Ethics committee approval is pending, approval expected in January 2007.

### **Study design**

Open label pilot study

### **Primary study design**

Interventional

### **Secondary study design**

Non randomised controlled trial

### **Study setting(s)**

Not specified

### **Study type(s)**

Treatment

### **Participant information sheet**

### **Health condition(s) or problem(s) studied**

Acute gout

### **Interventions**

Treatment with 100 mg anakinra daily subcutaneously for three days

### **Intervention Type**

Drug

### **Phase**

Not Specified

### **Drug/device/biological/vaccine name(s)**

Anakinra

### **Primary outcome measure**

1. Pain of arthritis
2. Signs of arthritis

### **Secondary outcome measures**

Biological markers of inflammation

**Overall study start date**

01/12/2006

**Completion date**

31/01/2007

## Eligibility

**Key inclusion criteria**

1. Acute gout as defined by American College of Rheumatology (ACR) criteria
2. Acute arthritis due to gout which is unresponsive to conventional therapy with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), colchicine or steroids
3. Patients with acute gout who have had side effects or intolerance to either NSAIDs, colchicine or steroids

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

10

**Key exclusion criteria**

1. Patients with on-going or untreated infectious diseases
2. Patients with rheumatoid arthritis, lupus or vasculitis
3. Patients concurrently treated with anti-Tumour Necrotising Factor (TNF) therapies
4. Patients with active cancer

**Date of first enrolment**

01/12/2006

**Date of final enrolment**

31/01/2007

## Locations

**Countries of recruitment**

Switzerland

**Study participating centre**

**Rheumatology Service**

Lausanne  
Switzerland  
1011

## Sponsor information

**Organisation**

University Hospital Complex of Vaud (Centre Hospitalier Universitaire Vaudois [CHUV])  
(Switzerland)

**Sponsor details**

Rheumatology  
Department of Medicine  
University of Lausanne  
Lausanne  
Switzerland  
1011  
+41 (0)21 314 14 50  
secretariat.so@chuv.ch

**Sponsor type**

University/education

**Website**

<http://www.chuv.ch/>

**ROR**

<https://ror.org/05a353079>

## Funder(s)

**Funder type**

University/education

**Funder Name**

Service of Rheumatology of the Centre Hospitalier Universitaire, Vaudois (Switzerland)

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	Results	01/09/2007		Yes	No